Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mangoceuticals (MGRX) EBITDA (2023 - 2025)

Historic EBITDA for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to -$7.5 million.

  • Mangoceuticals' EBITDA fell 32904.49% to -$7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.3 million, marking a year-over-year decrease of 11825.15%. This contributed to the annual value of -$8.0 million for FY2024, which is 1352.55% up from last year.
  • According to the latest figures from Q3 2025, Mangoceuticals' EBITDA is -$7.5 million, which was down 32904.49% from -$5.3 million recorded in Q2 2025.
  • Mangoceuticals' 5-year EBITDA high stood at -$1.7 million for Q4 2024, and its period low was -$7.5 million during Q3 2025.
  • For the 3-year period, Mangoceuticals' EBITDA averaged around -$3.2 million, with its median value being -$2.4 million (2024).
  • In the last 5 years, Mangoceuticals' EBITDA soared by 3467.17% in 2024 and then plummeted by 32904.49% in 2025.
  • Over the past 3 years, Mangoceuticals' EBITDA (Quarter) stood at -$2.6 million in 2023, then surged by 34.67% to -$1.7 million in 2024, then crashed by 349.61% to -$7.5 million in 2025.
  • Its last three reported values are -$7.5 million in Q3 2025, -$5.3 million for Q2 2025, and -$4.9 million during Q1 2025.